Catalysts for Virginia Commonwealth University

Virginia Commonwealth University — fluorouracil (Phase I Trial Initiation)

VIRGINIA COMMONWEALTH UNIVERSITY — Selective Vulnerability of Cholinergic Neurons in Alzheimer’s Disease

VIRGINIA COMMONWEALTH UNIVERSITY — Implications of Epigenetic Regulation in Congenital Myotonic Dystrophy throug...

VIRGINIA COMMONWEALTH UNIVERSITY — CE25-029 - Enhancing an existing prevention strategy to reduce intentional fi...

VIRGINIA COMMONWEALTH UNIVERSITY — Detection of novel environmental risk factors in the recently identified ALS ...

VIRGINIA COMMONWEALTH UNIVERSITY — Trajectories of pediatric asthma control: Examining sleep's influence in adol...

VIRGINIA COMMONWEALTH UNIVERSITY — Hydrogen Sulfide for the Prevention of Cisplatin-Induced Atherosclerosis

VIRGINIA COMMONWEALTH UNIVERSITY — Training Core

VIRGINIA COMMONWEALTH UNIVERSITY — Longitudinal Assessment of Molecular and Imaging Biomarkers in LGMDR1

VIRGINIA COMMONWEALTH UNIVERSITY — Novel 5-HT2A/mGluR5 Antagonist for Opioid Use Disorder

VIRGINIA COMMONWEALTH UNIVERSITY — The transcription factor RUNX1 is pivotal in TGFβ-activated cholangiocyte sig...

VIRGINIA COMMONWEALTH UNIVERSITY — Fenofibrate microemulsion for treating nitrogen mustard induced corneal injury

VIRGINIA COMMONWEALTH UNIVERSITY — Integrating a Prescription Produce Program within a Diabetes Prevention Progr...

VIRGINIA COMMONWEALTH UNIVERSITY — C18-Ceramide as an essential factor in iron dependent cell death

VIRGINIA COMMONWEALTH UNIVERSITY — Dissecting the co-occurrence of alcohol use/problems and suicidal behaviors: ...